Consistent with the anti-tumour effect of combined PARP and WEE1 inhibitors being dependent on T cells, the anti-tumour immune response to olaparib and AZD1775 treatment was not as pronounced in the AT3 compared with the AT3OVA tumours. The gene discussed is WEE1; the disease is neoplasm.